Mabpharm Limited announced plans to revise its Memorandum and Articles of Association to align with recent regulatory changes and enhance corporate flexibility.

Key proposed amendments: 1. Compliance and Treasury Shares: The updated document will reflect the latest requirements under Hong Kong’s Companies Ordinance (Chapter 622) and the Listing Rules, expressly permitting the holding of treasury shares for potential resale or transfer under specified conditions.

2. Meeting Flexibility: Provisions will be added to facilitate hybrid or fully electronic general meetings, broadening shareholder participation options.

3. Paperless Regime: The revisions incorporate the expanded paperless listing framework and electronic dissemination of corporate communications mandated by the Stock Exchange of Hong Kong.

4. Housekeeping Updates: Consequential and technical changes will be made to ensure consistency with Cayman Islands law and the Listing Rules.

Implementation Process: • The amendments and adoption of the amended and restated Memorandum and Articles require approval via special resolution at the forthcoming annual general meeting. • A circular detailing the changes and the AGM notice will be distributed to shareholders in accordance with Listing Rule procedures.

Board Composition (as of 26 March 2026): • Executive Directors: Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng, Dr. Qian Weizhu • Non-Executive Directors: Mr. Jiao Shuge (Chairman), Mr. Cen Jialin • Independent Non-Executive Directors: Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Louis Ho Ming Leung, Dr. Tao Qian

The company emphasized that final adoption of the revised governance framework is contingent on shareholder approval at the AGM.